Schizophrenia
MIT Press (Verlag)
978-0-262-01962-0 (ISBN)
- Keine Verlagsinformationen verfügbar
- Artikel merken
Despite major advances in methodology and thousands of published studies every year, treatment outcomes in schizophrenia have not improved over the last fifty years. Moreover, we still lack strategies for prevention and we do not yet understand how the interaction of genetic, developmental, and environmental factors contribute to the disorder. In this book, leading researchers consider conceptual and technical obstacles to progress in understanding schizophrenia and suggest novel strategies for advancing research and treatment.
The contributors address a wide range of critical issues: the construct of schizophrenia itself; etiology, risk, prediction, and prevention; different methods of modeling the disorder; and treatment development and delivery. They identify crucial gaps in our knowledge and offer creative but feasible suggestions. These strategies include viewing schizophrenia as a heterogeneous group of conditions; adopting specific new approaches to prediction and early intervention; developing better integration of data across genetics, imaging, perception, cognition, phenomenology, and other fields; and moving toward an evidence-based, personalized approach to treatment requiring rational clinical decision-making to reduce functional disability.
Contributors
Robert Bittner, Robert W. Buchanan, Kristin S. Cadenhead, William T. Carpenter, Jr., Aiden Corvin, Daniel Durstewitz, Andre A. Fenton, Camilo de la Fuente-Sandoval, Jay A. Gingrich, Joshua A. Gordon, Chloe Gott, Peter B. Jones, Rene S. Kahn, Richard Keefe, Wolfgang Kelsch, James L. Kennedy, Matcheri S. Keshavan, Angus W. MacDonald III, Anil K. Malhotra, John McGrath, Andreas Meyer-Lindenberg, Kevin J. Mitchell, Bita Moghaddam, Vera A. Morgan, Craig Morgan, Kim T. Mueser, Karoly Nikolich, Patricio O'Donnell, Michael O'Donovan, William A. Phillips, Wulf Roessler, Louis Sass, Akira Sawa, Jeremy K. Seamans, Steven M. Silverstein, William Spaulding, Sharmili Sritharan, Heike Tost, Peter Uhlhaas, Aristotle Voineskos, Michele Wessa, Leanne M. Williams, Ashley Wilson, Til Wykes
Steven M. Silverstein is Director of the Division of Schizophrenia Research at University Behavioral HealthCare, Rutgers Biomedical and Health Services, Rutgers University. Bita Moghaddam is leading researcher in the field of neuropsychopharmacology. She is Chair of the Department of Behavioral Neuroscience and Ruth Matarazzo Professor at Oregon Health and Science University in Portland. Til Wykes is Professor of Clinical Psychology and Rehabilitation at Kings College London, Director of the National Institute for Health Research Mental Health Research Network, Codirector of the Service User Research Enterprise, and editor of the journal Mental Health. Steven M. Silverstein is Director of the Division of Schizophrenia Research at University Behavioral HealthCare, Rutgers Biomedical and Health Services, Rutgers University. Bita Moghaddam is leading researcher in the field of neuropsychopharmacology. She is Chair of the Department of Behavioral Neuroscience and Ruth Matarazzo Professor at Oregon Health and Science University in Portland. Til Wykes is Professor of Clinical Psychology and Rehabilitation at Kings College London, Director of the National Institute for Health Research Mental Health Research Network, Codirector of the Service User Research Enterprise, and editor of the journal Mental Health. Peter J. Uhlhaas is Professor for Early Detection and Intervention of Mental Disorders at the Department of Child and Adolescent Psychiatry, Charite - Universita tsmedizin Berlin.. Joshua A. Gordon is Director of the National Institute of Mental Health (NIMH). William A. Phillips is Emeritus Professor of Neuropsychology at the University of Stirling and Adjunct Fellow of the Frankfurt Institute for Advanced Studies. Karoly Nikolich is Consulting Professor in the Department of Psychiatry at Stanford University Medical School as well as Founder of Circuit Therapeutics and Chairman of Alkahest, two biotechnology companies that grew out of research done at Stanford.
| Reihe/Serie | Schizophrenia ; 13 |
|---|---|
| Verlagsort | Cambridge, Mass. |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Gewicht | 880 g |
| Themenwelt | Geisteswissenschaften ► Psychologie ► Klinische Psychologie |
| Geisteswissenschaften ► Psychologie ► Persönlichkeitsstörungen | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Psychiatrie / Psychotherapie | |
| Naturwissenschaften ► Biologie ► Zoologie | |
| ISBN-10 | 0-262-01962-0 / 0262019620 |
| ISBN-13 | 978-0-262-01962-0 / 9780262019620 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
